Mechanisms of disease

New mechanisms of antiarrhythmic actions

Robert F. Gilmour, Douglas P. Zipes

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cardiac arrhythmias are a leading cause of morbidity and mortality in many developed countries. Despite intensive investigation, the cellular mechanisms for most cardiac arrhythmias have not been clearly established. As a consequence, drug therapy for most forms of atrial and ventricular arrhythmias remains largely empirical and ineffective, leading to the increased use of nonpharmacologic treatments. Clearly, new approaches to the prevention of cardiac arrhythmias are needed. Here we review the current experimental basis for several promising antiarrhythmic strategies, with a focus on those targeted against atrial and ventricular fibrillation. Although none of these strategies is yet ready for clinical application, they provide a basis for cautious optimism that effective pharmacologic therapy for fatal cardiac rhythm disturbances could be forthcoming.

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalNature Clinical Practice Cardiovascular Medicine
Volume1
Issue number1
DOIs
StatePublished - Nov 2004

Fingerprint

Cardiac Arrhythmias
Ventricular Fibrillation
Developed Countries
Atrial Fibrillation
Morbidity
Drug Therapy
Mortality
Therapeutics

Keywords

  • Antiarrhythmic drug
  • Connexin
  • Gene therapy
  • Ion channel
  • Restitution

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mechanisms of disease : New mechanisms of antiarrhythmic actions. / Gilmour, Robert F.; Zipes, Douglas P.

In: Nature Clinical Practice Cardiovascular Medicine, Vol. 1, No. 1, 11.2004, p. 37-41.

Research output: Contribution to journalArticle

Gilmour, Robert F. ; Zipes, Douglas P. / Mechanisms of disease : New mechanisms of antiarrhythmic actions. In: Nature Clinical Practice Cardiovascular Medicine. 2004 ; Vol. 1, No. 1. pp. 37-41.
@article{d5db40ea062b4a8eaac8ae8b7f3c41fd,
title = "Mechanisms of disease: New mechanisms of antiarrhythmic actions",
abstract = "Cardiac arrhythmias are a leading cause of morbidity and mortality in many developed countries. Despite intensive investigation, the cellular mechanisms for most cardiac arrhythmias have not been clearly established. As a consequence, drug therapy for most forms of atrial and ventricular arrhythmias remains largely empirical and ineffective, leading to the increased use of nonpharmacologic treatments. Clearly, new approaches to the prevention of cardiac arrhythmias are needed. Here we review the current experimental basis for several promising antiarrhythmic strategies, with a focus on those targeted against atrial and ventricular fibrillation. Although none of these strategies is yet ready for clinical application, they provide a basis for cautious optimism that effective pharmacologic therapy for fatal cardiac rhythm disturbances could be forthcoming.",
keywords = "Antiarrhythmic drug, Connexin, Gene therapy, Ion channel, Restitution",
author = "Gilmour, {Robert F.} and Zipes, {Douglas P.}",
year = "2004",
month = "11",
doi = "10.1038/ncpcardio0024",
language = "English",
volume = "1",
pages = "37--41",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Mechanisms of disease

T2 - New mechanisms of antiarrhythmic actions

AU - Gilmour, Robert F.

AU - Zipes, Douglas P.

PY - 2004/11

Y1 - 2004/11

N2 - Cardiac arrhythmias are a leading cause of morbidity and mortality in many developed countries. Despite intensive investigation, the cellular mechanisms for most cardiac arrhythmias have not been clearly established. As a consequence, drug therapy for most forms of atrial and ventricular arrhythmias remains largely empirical and ineffective, leading to the increased use of nonpharmacologic treatments. Clearly, new approaches to the prevention of cardiac arrhythmias are needed. Here we review the current experimental basis for several promising antiarrhythmic strategies, with a focus on those targeted against atrial and ventricular fibrillation. Although none of these strategies is yet ready for clinical application, they provide a basis for cautious optimism that effective pharmacologic therapy for fatal cardiac rhythm disturbances could be forthcoming.

AB - Cardiac arrhythmias are a leading cause of morbidity and mortality in many developed countries. Despite intensive investigation, the cellular mechanisms for most cardiac arrhythmias have not been clearly established. As a consequence, drug therapy for most forms of atrial and ventricular arrhythmias remains largely empirical and ineffective, leading to the increased use of nonpharmacologic treatments. Clearly, new approaches to the prevention of cardiac arrhythmias are needed. Here we review the current experimental basis for several promising antiarrhythmic strategies, with a focus on those targeted against atrial and ventricular fibrillation. Although none of these strategies is yet ready for clinical application, they provide a basis for cautious optimism that effective pharmacologic therapy for fatal cardiac rhythm disturbances could be forthcoming.

KW - Antiarrhythmic drug

KW - Connexin

KW - Gene therapy

KW - Ion channel

KW - Restitution

UR - http://www.scopus.com/inward/record.url?scp=20444433923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444433923&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio0024

DO - 10.1038/ncpcardio0024

M3 - Article

VL - 1

SP - 37

EP - 41

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 1

ER -